179 related articles for article (PubMed ID: 28479111)
21. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant Effects of
Rezaei A; Shahabi G; Faezi S; Shafiee Ardestani M; Shirzad H; Azadmanesh K; Mirzajani E; Shajiei A; Mahdavi M
Viral Immunol; 2022 Mar; 35(2):150-158. PubMed ID: 35319970
[TBL] [Abstract][Full Text] [Related]
23. New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin.
Bargieri DY; Rosa DS; Braga CJ; Carvalho BO; Costa FT; Espíndola NM; Vaz AJ; Soares IS; Ferreira LC; Rodrigues MM
Vaccine; 2008 Nov; 26(48):6132-42. PubMed ID: 18804504
[TBL] [Abstract][Full Text] [Related]
24. Novel HIV IL-4R antagonist vaccine strategy can induce both high avidity CD8 T and B cell immunity with greater protective efficacy.
Jackson RJ; Worley M; Trivedi S; Ranasinghe C
Vaccine; 2014 Sep; 32(43):5703-14. PubMed ID: 25151041
[TBL] [Abstract][Full Text] [Related]
25. Immunopotentiation of Different Adjuvants on Humoral and Cellular Immune Responses Induced by HA1-2 Subunit Vaccines of H7N9 Influenza in Mice.
Song L; Xiong D; Hu M; Kang X; Pan Z; Jiao X
PLoS One; 2016; 11(3):e0150678. PubMed ID: 26930068
[TBL] [Abstract][Full Text] [Related]
26. The new nano-complex, Hep-c, improves the immunogenicity of the hepatitis B vaccine.
Fakharzadeh S; Kalanaky S; Hafizi M; Goya MM; Masoumi Z; Namaki S; Shakeri N; Abbasi M; Mahdavi M; Nazaran MH
Vaccine; 2013 May; 31(22):2591-7. PubMed ID: 23583463
[TBL] [Abstract][Full Text] [Related]
27. Prime/boost immunization with HIV-1 MPER-V3 fusion construct enhances humoral and cellular immune responses.
Bolhassani A; Kardani K; Vahabpour R; Habibzadeh N; Aghasadeghi MR; Sadat SM; Agi E
Immunol Lett; 2015 Dec; 168(2):366-73. PubMed ID: 26518142
[TBL] [Abstract][Full Text] [Related]
28. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine.
Blazevic V; Männik A; Malm M; Sikut R; Valtavaara M; Toots U; Ustav M; Krohn K
AIDS Res Hum Retroviruses; 2006 Jul; 22(7):667-77. PubMed ID: 16831091
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of Immune Responses by Guanosine-Based Particles in DNA Plasmid Formulations against Infectious Diseases.
Santos S; Ramírez M; Miranda E; Reyes N; Martínez O; Acosta-Santiago M; Rivera JM; Otero M
J Immunol Res; 2019; 2019():3409371. PubMed ID: 31240233
[TBL] [Abstract][Full Text] [Related]
30. Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice.
Asadi Karam MR; Oloomi M; Mahdavi M; Habibi M; Bouzari S
Vaccine; 2013 Feb; 31(8):1210-6. PubMed ID: 23306365
[TBL] [Abstract][Full Text] [Related]
31. Characterization of humoral and cellular immune responses in mice induced by immunization with HIV-1 Nef regulatory protein encapsulated in poly(DL-lactide-co-glycolide) microparticles.
Moureau C; Vidal PL; Bennasser Y; Moynier M; Nicaise Y; Aussillous M; Barthelemy S; Montagnier L; Bahraoui E
Mol Immunol; 2002 Jan; 38(8):607-18. PubMed ID: 11792429
[TBL] [Abstract][Full Text] [Related]
32. Determination immunogenic property of truncated MrpH.FliC as a vaccine candidate against urinary tract infections caused by Proteus mirabilis.
Bameri Z; Asadi Karam MR; Habibi M; Ehsani P; Bouzari S
Microb Pathog; 2018 Jan; 114():99-106. PubMed ID: 29138084
[TBL] [Abstract][Full Text] [Related]
33. MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.
Kutscher S; Allgayer S; Dembek CJ; Bogner JR; Protzer U; Goebel FD; Erfle V; Cosma A
Gene Ther; 2010 Nov; 17(11):1372-83. PubMed ID: 20535218
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the Efficacy of HIV-1 Nef-Tat-Gp160-p24 Polyepitope Vaccine Candidate with Nef Protein in Different Immunization Strategies.
Namazi F; Davoodi S; Bolhassani A
Curr Drug Deliv; 2022; 19(1):142-156. PubMed ID: 33655833
[TBL] [Abstract][Full Text] [Related]
35. Attenuated nef DNA vaccine construct induces cellular immune response: role in HIV-1 multiprotein vaccine.
Majumder B; Gray B; McBurney S; Schaefer TM; Dentchev T; Mahalingam S; Reinhart TA; Ayyavoo V
Immunol Lett; 2003 Oct; 89(2-3):207-14. PubMed ID: 14556980
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype.
McNicholl JM; Bond KB; Ruhadze ER; Olsen MR; Takayama K; Hunter RL
AIDS Res Hum Retroviruses; 1998 Nov; 14(16):1457-71. PubMed ID: 9824324
[TBL] [Abstract][Full Text] [Related]
37. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
[TBL] [Abstract][Full Text] [Related]
38. Comparative study of immune responses induced after immunization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin promoter.
Cazeaux N; Bennasser Y; Vidal PL; Li Z; Paulin D; Bahraoui E
Vaccine; 2002 Sep; 20(27-28):3322-31. PubMed ID: 12213402
[TBL] [Abstract][Full Text] [Related]
39. Formulation of chitosan with the polyepitope HIV-1 protein candidate vaccine efficiently boosts cellular immune responses in mice.
Jazaeri EO; Mahdavi A; Abdoli A
Pathog Dis; 2017 Nov; 75(8):. PubMed ID: 28911033
[TBL] [Abstract][Full Text] [Related]
40. Modulation of Th1/Th2 immune responses to HIV-1 Tat by new pro-GSH molecules.
Fraternale A; Paoletti MF; Dominici S; Buondelmonte C; Caputo A; Castaldello A; Tripiciano A; Cafaro A; Palamara AT; Sgarbanti R; Garaci E; Ensoli B; Magnani M
Vaccine; 2011 Sep; 29(40):6823-9. PubMed ID: 21816192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
